TGTX
NASD TG Therapeutics, Inc.$53.27 ↓ -0.07 (-0.13%) Trading Down from the previous close of $53.34
- YTD change
- +78.70%
- vs 20-day SMA
- -3.57%
- vs 200-day SMA
- +27.55%
Price ranges
Price & Performance
+18.71 (+54.03%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 10.2% away from all-time highs of $59.30
- TGTX is up 79% since the beginning of the year
- TGTX is up 52% over the past 12 months
- TGTX is down 4% over the past 1 month
- 21% of all TGTX investors are betting against TGTX
TGTX reads neutral: price sits above one of the two key moving averages, the 12-month move is +52.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- -0.65%
- vs 8-day SMA
- -1.41%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.